Nextcure

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nextcure's solid footing should sustain it despite Eli Lilly walking away from an R&D pact.

What Does the Future Hold for Nextcure?

Beyond Meat

Cortexyme Inc

IGM Biosciences Inc

Inmode Ltd

Karuna Therapeutics Inc

Palomar

Shockwave Medical

Turning Point Therapeutics

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who didn’t buy into the hype of more familiar names like Uber or Lyft.

Non-Household Names Topped the List of IPO Winners in 2019

Applied Therapeutics Inc

Aprea Therapeutics

BioNTech SE

Glaukos

Rapt Therapeutics Inc

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

These Were the 10 Best IPOs of 2019

The recent volatility hasn't been ideal, but it has certainly put the newly public company on the radar of investors.

Is NextCure a Buy?

BELTSVILLE, Md., Nov.  19, 2019  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $150 million. NextCure’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “NXTC.”

NextCure Announces Closing of Public Offering

BELTSVILLE, Md., Nov.  14, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 611,578 shares of its common stock at the public offering price less the underwriting discounts and commissions. All of the common stock to be sold in the offering are being offered by NextCure. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $150 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about November 19, 2019, subject to the satisfaction of customary closing conditions.

NextCure Announces Pricing of Public Offering of Common Stock

NextCure's Big Rise And Fall, And Other Headlines: The Good, Bad And Ugly Of Biopharma

BELTSVILLE, Md., Nov.  12, 2019  (GLOBE NEWSWIRE) --  NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public offering of 3,200,000 shares of its common stock. In addition, NextCure intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the common stock to be sold in the offering will be offered by NextCure. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

NextCure Announces Proposed Public Offering of Common Stock

NextCure Inc (NASDAQ: NXTC) shares are settling down after the volatile run in the past few sessions.

Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside

NextCure Inc. (NASDAQ: NXTC) updated clinical results from its early-stage cancer study at the Society for Immunotherapy of Cancer (SITC) annual meeting.

Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment

Highly anticipated clinical trial results didn't continue a promising trend from a smaller number of patients.

Here's Why NextCure Crashed Today

NextCure Inc (NASDAQ: NXTC) shares, which posted a stellar gain of about 250% on Nov.

NextCure Shares Give Back Some Gains After Data Readout

BELTSVILLE, Md., Nov.  09, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that updated clinical results from the Phase 1 portion of its ongoing trial with NC318, a monoclonal antibody targeting Siglec-15 (S15), were presented at the SITC annual meeting. S15 is a novel immunomodulatory protein that is expressed on highly immunosuppressive cells called M2 macrophages and on tumor cells. In addition, NextCure announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial of NC318.

NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

Good news from an extremely small number of patients led to today's enormous bump.

Here's Why NextCure Stock Blew Through the Roof Today

I'm highly selective with my early investments, and you should be, too

WeWork IPO was a Failure – These 2 IPO Stocks are Surging

BELTSVILLE, Md., Oct.  02, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the promotion of Timothy Mayer, Ph.D. from Senior Vice President, Corporate Development to Chief Operating Officer.

NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

BELTSVILLE, Md., Oct.  01, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical data from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of NC318 in patients with advanced or metastatic solid tumors will be presented in an oral session at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-10, 2019 in National Harbor, Maryland.

NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

The initial public offering class of 2018 and 2019 has been very mixed. There have been some great winners, but there also have been some very well-known unicorns that have flopped.

Is NextCure the Next Big Cancer Biotech Every Investor Missed?

BELTSVILLE, Md., Sept.  03, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on September 10, 2019 at 10:00 am ET.

NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference

Personalis Inc

The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.

2 Small-Cap Biotech IPOs You Should Know About

News for Nextcure Stock (NXTC)